Shaped mass composition comprising exenatide
Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
1. A shaped mass comprising exenatide for treatment of diabetes or other glucose regulation disorder, wherein a weight percentage of exenatide in the shaped mass is at least about 60%, and wherein at least about 80% of the exenatide in the shaped mass is biologically active, the shaped mass having a density in a range of about 0.95 to about 1.15 mg/mm 3 , wherein the shaped mass further comprises an excipient.
2. The shaped mass of claim 1 , wherein a weight percentage of exenatide in the shaped mass is in a range of about 80 to 95%.
3. The shaped mass of claim 1 , wherein the shaped mass comprises between about 1 to 5 mg of exenatide.
4. The shaped mass of claim 1 , wherein the shaped mass has a cylindrical shape.
5. The shaped mass of claim 1 , wherein the shaped mass has a tablet or pellet shape.
6. The shaped mass of claim 1 , wherein the shaped mass has a tissue penetrating shape.
7. The shaped mass of claim 1 , wherein the shaped mass comprises a biodegradable material which breaks down in intestinal wall tissue so as to release the exenatide.
8. The shaped mass of claim 1 , wherein the excipient comprises PEG.
9. The shaped mass of claim 1 , wherein the excipient comprises at least one of a lubricant, a binding agent or a bulking agent.
10. The shaped mass of claim 9 , wherein the binding agent is povidone.
11. The shaped mass of claim 9 , wherein the bulking agent is mannitol.
12. The shaped mass of claim 9 , wherein the lubricant is PEG.
13. The shaped mass of claim 9 , wherein the lubricant is PEG, the bulking agent is mannitol, and the binder is povidone.